New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
04:55 EDTA, A, A, A, RHHBY, RHHBY, RHHBY, RHHBY, PKI, PKI, PKI, PKI, LIFE, LIFE, LIFE, LIFE, ILMN, ILMN, ILMN, ILMN, QGEN, QGEN, QGEN, QGEN, PACB, PACB, PACB, PACBG Corp to host a meeting
14th Annual Advances in Genome Biology and Technology Meeting is being held on Marco Island, Florida on February 20-23.
News For A;RHHBY;PKI;LIFE;ILMN;QGEN;PACB From The Last 14 Days
Check below for free stories on A;RHHBY;PKI;LIFE;ILMN;QGEN;PACB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 23, 2014
06:16 EDTRHHBYPharmaceutical companies narrowing focus, WSJ reports
Subscribe for More Information
April 22, 2014
19:09 EDTILMNOn The Fly: After Hours Movers
Subscribe for More Information
16:22 EDTILMNIllumina trades higher after results, first look
In the extended session shares are trading up over 6% to $157. At that price, next resistance is at $159.72. Support is at $155.86.
16:14 EDTILMNIllumina raises FY14 EPS view to $2.10-$2.15, consensus $2.05
The company has increased projections to approximately 21% to 23% revenue growth, consensus $1.68B.
16:13 EDTILMNIllumina reports Q1 adjusted EPS 53c, consensus 44c
Subscribe for More Information
15:32 EDTILMNNotable companies reporting after market close
Subscribe for More Information
April 21, 2014
12:44 EDTRHHBYRoche management to meet with Jefferies
Subscribe for More Information
10:11 EDTILMNIllumina has a conference call hosted by JPMorgan
JPMorgan Analyst Peterson will host a conference call with CFO Marc Stapley on April 25 at 11 am.
07:58 EDTILMNIllumina May volatility elevated at 68 into Q1 and outlook
Subscribe for More Information
April 19, 2014
11:12 EDTRHHBYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 17, 2014
06:18 EDTRHHBYEMA warns that stolen Roche drug found on market
The European Medicines Agency has been informed that vials of the cancer medicine Herceptin, thought to have been stolen in Italy, including from hospitals, have been tampered with and re-introduced under false credentials into the supply chain in some countries. This is currently being investigated by Member State authorities and updates will be provided as more information becomes available. Italian law enforcement authorities are currently investigating the theft and are looking at whether other medicines may also be affected. No affected product has so far been identified at hospital level and there are no reports that any harm has come to patients in relation to the falsified medicine and authorities are working to avoid this. The marketing authorisation holder for Herceptin is Roche.
April 16, 2014
07:32 EDTRHHBYRegeneron may be taking market share from Roche, says Brean Capital
Subscribe for More Information
April 15, 2014
09:02 EDTRHHBYRoche confirms FY outlook for low-to mid-single digit growth in sales
Subscribe for More Information
09:01 EDTRHHBYRoche reports Q1 sales CHF11.496B vs. CHF11.589B a year ago
Roche reported Q1 group sales rose 5% at constant exchange rates and fell 1% in Swiss francs compared to the prior year. Pharma sales were up 4%, with continued growth of Avastin, MabThera/Rituxan, Actemra/RoActemra and Herceptin compensating for expected decline in Xeloda sales, while Diagnostics division sales were up 7%. Roche CEO Severin Schwan said: “Both the Pharma and Diagnostics Divisions posted solid growth in the first quarter. I am particularly pleased with the strong uptake of our recently launched medicines Perjeta and Kadcyla for HER2-positive breast cancer."
08:23 EDTRHHBYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:19 EDTRHHBYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
06:32 EDTRHHBYPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 10, 2014
16:02 EDTQGENQIAGEN acquires exclusive worldwide license to biomarker calreticulin
Subscribe for More Information
16:00 EDTAOptions Update; April 10, 2014
Subscribe for More Information
11:42 EDTRHHBYReport claims Tamiflu, Relenza do little to prevent the spread of flu
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use